![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.175 | 0.15 | 0.20 | 329,465 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -859k | -0.0010 | -1.70 | 1.43M |
TIDMNFX
RNS Number : 5200I
Nuformix PLC
05 December 2022
5 December 2022
Nuformix plc
("Nuformix" or the "Company")
Resignation of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the resignation of Jeffreys Henry LLP ("Jeffreys Henry") as auditors to the Company. Section 519 of the Companies Act 2006 (the "Act") requires Jeffreys Henry to send a statement of the reasons for ceasing to hold office. They have stated that in accordance with Section 519 of the Act, they are ceasing to hold office due to the following reason:
"Jeffreys Henry LLP have resigned as auditor on the grounds that the firm has taken the decision not to register as an auditor eligible to undertake Public Interest Entity audits."
There are no circumstances connected with Jeffreys Henry ceasing to hold office as auditor which they consider should be brought to the attention of the Company's members or creditors. As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.
The appointment of a new auditor will be announced in due course following the completion of a tender process.
Enquiries:
Nuformix plc Dr Julian Gilbert, Non-executive Via IFC Advisory Chairman Stanford Capital Partners Limited Tom Price / Patrick Claridge (Corporate Finance) +44 (0) 20 3650 3650 John Howes (Corporate Broking) +44 (0) 20 3650 3652 IFC Advisory Limited Tim Metcalfe +44 (0) 20 3934 6630 Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPFLFSTFLLSIIF
(END) Dow Jones Newswires
December 05, 2022 02:00 ET (07:00 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions